Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$161.41
-3.5%
$174.94
$130.96
$182.89
$285.80B0.585.56 million shs2.65 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$146.25
-0.4%
$155.47
$143.13
$175.97
$352.43B0.537.31 million shs1.13 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$734.63
+1.3%
$762.75
$380.77
$800.78
$698.02B0.343.00 million shs517,174 shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.33
+0.3%
$27.01
$25.20
$40.37
$143.43B0.6141.54 million shs8.70 million shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.33%+1.59%-6.65%+1.75%+3.39%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-1.15%+0.74%-5.75%-7.96%-9.72%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-1.00%-2.83%-6.49%+13.40%+92.65%
Pfizer Inc. stock logo
PFE
Pfizer
-3.81%-0.49%-8.45%-8.03%-34.61%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.8749 of 5 stars
2.43.04.23.93.72.52.5
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.9338 of 5 stars
3.23.04.23.93.62.51.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8185 of 5 stars
2.43.02.54.03.02.53.1
Pfizer Inc. stock logo
PFE
Pfizer
4.9782 of 5 stars
3.23.04.24.83.11.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.77
Moderate Buy$177.439.92% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.46
Hold$175.8620.24% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$728.05-0.90% Downside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3343.44% Upside

Current Analyst Ratings

Latest JNJ, LLY, PFE, and ABBV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$169.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$168.00 ➝ $167.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$181.00 ➝ $175.00
4/15/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/3/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
4/2/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$675.00 ➝ $895.00
4/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.26$15.21 per share10.61$5.78 per share27.93
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$85.16B4.14$13.45 per share10.87$28.57 per share5.12
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B20.46$7.65 per share96.01$11.44 per share64.22
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.45$2.87 per share8.83$15.81 per share1.60

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$2.7359.1213.312.138.95%162.28%14.62%4/26/2024 (Confirmed)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$16.049.1213.382.4545.26%36.43%15.01%7/18/2024 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80126.6639.711.6015.36%51.22%9.94%4/30/2024 (Confirmed)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3670.369.141.183.62%10.88%4.91%5/1/2024 (Confirmed)

Latest JNJ, LLY, PFE, and ABBV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/30/2024N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.61N/A-$2.61N/AN/AN/A  
4/26/2024Q1 24
AbbVie Inc. stock logo
ABBV
AbbVie
$2.20$2.31+$0.11N/A$11.93 billion$12.31 billion  
4/16/2024Q1 24
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.64$2.71+$0.07$3.22$21.39 billion$21.38 billion    
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    
2/2/202412/31/2023
AbbVie Inc. stock logo
ABBV
AbbVie
$2.76$2.79+$0.03$5.12$14.02 billion$14.30 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.84%+7.84%227.11%52 Years
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.763.25%+5.70%29.68%63 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.71%+15.15%89.66%10 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.63%+2.57%466.67%15 Years

Latest JNJ, LLY, PFE, and ABBV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
4/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.36%5/20/20245/21/20246/4/2024
2/15/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.54%4/12/20244/15/20245/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
5.02
0.87
0.76
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.38
1.16
0.91
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
131,9002.41 billion2.41 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

JNJ, LLY, PFE, and ABBV Headlines

SourceHeadline
Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key MetricsGear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics
zacks.com - April 26 at 10:21 AM
Pfizer Receives FDA Approval for Bleeding Disorder TreatmentPfizer Receives FDA Approval for Bleeding Disorder Treatment
barrons.com - April 26 at 9:35 AM
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 StocksWant $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
fool.com - April 26 at 7:45 AM
Pfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia BPfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia B
marketwatch.com - April 26 at 7:33 AM
Pfizers Beqvez Receives FDA Approval For Treatment Of Adults With Hemophilia BPfizer's Beqvez Receives FDA Approval For Treatment Of Adults With Hemophilia B
markets.businessinsider.com - April 26 at 7:33 AM
US FDA approves Pfizers gene therapy for rare bleeding disorderUS FDA approves Pfizer's gene therapy for rare bleeding disorder
reuters.com - April 26 at 7:33 AM
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia BU.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
finance.yahoo.com - April 26 at 7:33 AM
Pfizer Now Rivals The Worlds Most Expensive Medicine After FDA Approves Gene TherapyPfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
finance.yahoo.com - April 26 at 7:33 AM
UPDATE 2-US FDA approves Pfizers gene therapy for rare bleeding disorderUPDATE 2-US FDA approves Pfizer's gene therapy for rare bleeding disorder
finance.yahoo.com - April 26 at 7:33 AM
FDA approves Pfizers first gene therapy for rare inherited bleeding disorderFDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
cnbc.com - April 26 at 7:02 AM
U.S. FDA Approves Pfizers BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia BU.S. FDA Approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
businesswire.com - April 26 at 6:45 AM
Pfizer (NYSE:PFE) Trading Down 2.5%Pfizer (NYSE:PFE) Trading Down 2.5%
marketbeat.com - April 25 at 6:18 PM
Syon Capital LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)Syon Capital LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 25 at 5:33 PM
3 Bargain Stocks Near 52-week Lows3 Bargain Stocks Near 52-week Lows
marketbeat.com - April 25 at 9:46 AM
3 Bargain Stocks Near 52-week Lows (PFE)3 Bargain Stocks Near 52-week Lows (PFE)
marketbeat.com - April 25 at 9:46 AM
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technologyGlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
reuters.com - April 25 at 9:40 AM
UPDATE 1-Ad group WPP reports 1.6% drop in first-quarter organic growthUPDATE 1-Ad group WPP reports 1.6% drop in first-quarter organic growth
finance.yahoo.com - April 25 at 8:58 AM
Pfizer declares $0.42 dividendPfizer declares $0.42 dividend
msn.com - April 24 at 8:10 PM
Pfizer Inc. (NYSE:PFE) Shares Sold by Alaska Permanent Fund CorpPfizer Inc. (NYSE:PFE) Shares Sold by Alaska Permanent Fund Corp
marketbeat.com - April 24 at 5:28 PM
Pfizer Inc. (NYSE:PFE) to Issue Quarterly Dividend of $0.42Pfizer Inc. (NYSE:PFE) to Issue Quarterly Dividend of $0.42
marketbeat.com - April 24 at 5:22 PM
Pfizer Declares Second-Quarter 2024 DividendPfizer Declares Second-Quarter 2024 Dividend
businesswire.com - April 24 at 4:37 PM
Pfizer (NYSE:PFE) Trading Down 0.5%Pfizer (NYSE:PFE) Trading Down 0.5%
marketbeat.com - April 24 at 4:22 PM
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
zacks.com - April 24 at 1:06 PM
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
zacks.com - April 24 at 11:06 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.